Market Overview

Akorn Shares Rally Following Increased Price Target

Related AKRX
ETFs For The Next Pharma Takeover Candidates
5 Mid-Caps With Unsustainable Cash Burn Rates
Premarket Biotech Digest: PD-1 Inhibitors, Mylan Takeover Canceled, NantKwest IPO Largest (Seeking Alpha)

Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40.

The note cited a "game changing" effect if Akorn matches Taro Pharmaceutical Industries' recent price increases in topical generics.

Shares are currently up 5.25 percent at $34.99.

Latest Ratings for AKRX

Jul 2015SusquehannaInitiates Coverage onNeutral
Jul 2015SusquehannaInitiates Coverage onNeutral
Jun 2015Raymond JamesInitiates Coverage onOutperform

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: NeedhamAnalyst Color News Price Target Analyst Ratings


Related Articles (AKRX)

Get Benzinga's Newsletters